Live-attenuated measles virus vaccine confers cell contact loss and apoptosis of ovarian cancer cells via ROS-induced silencing of E-cadherin by methylation

Cancer Letters

Volumn 318, Issue 1, 2012, Pages 14-25

  Zhou, Shengtao ^a   Li, Yuhua ^b   Huang, Fuqiang ^a   Zhang, Boya ^a   Yi, Tao ^a   Li, Zhengyu ^a   Luo, Hong ^a   He, Xiang ^a   Zhong, Qian ^a   Bian, Ce ^a   Lin, Xiaojuan ^a   Qi, Xiaorong ^a   Liu, Ping ^a   Huang, Canhua ^a   Zhao, Xia ^a   Wei, Yuquan ^a  

^a SICHUAN UNIVERSITY   (China)

^b NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

Anti cancer effects; Live attenuated measles virus vaccine; Ovarian cancer; Proteomics

Indexed keywords

DNA METHYLTRANSFERASE 3A; MEASLES VACCINE; REACTIVE OXYGEN METABOLITE; UVOMORULIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CONTACT; CELL LOSS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENCY; ENZYME REGULATION; EPIGENETICS; EXTRACELLULAR MATRIX; FEMALE; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEOMICS; UPREGULATION;

APOPTOSIS; BLOTTING, WESTERN; CADHERINS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; HUMANS; MEASLES VACCINE; OVARIAN NEOPLASMS; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MEASLES VIRUS;

EID: 84862782595     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.10.038     Document Type: Article

References (46)

1. Kulasingam V., Pavlou M.P., Diamandis E.P. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat. Rev. Cancer 2010, 10:371-378.
2. Peng K.W., Hadac E.M., Anderson B.D., Myers R., Harvey M., Greiner S.M., Soeffker D., Federspiel M.J., Russell S.J. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gen. Ther. 2006, 13:732-738.
3. Phuong L.K., Allen C., Peng K.W., Giannini C., Greiner S., TenEyck C.J., Mishra P.K., Macura S.I., Russell S.J., Galanis E.C. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 2003, 63:462-2469.
4. Studebaker A.W., Kreofsky C.R., Pierson C.R., Russell S.J., Galanis E., Raffel C. Treatment of medulloblastoma with a modified measles virus. Neuro-Oncol. 2010, 12:1034-1042.
5. Msaouel P.L., Lankov D., Allen C., Morrs J.C., von Messling V., Cattaneo R., Koutsilieris M., Russell S.J., Galanis E. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 2009, 69:82-91.
6. Msaouel P.L., Iankov D., Allen C., Aderca I., Federspiel M.J., Tindall D.J., Morris J.C., Koutsilieris M., Russell S.J., Galanis E. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol. Ther. 2009, 17:2041-2048.
7. Splinter B.B., Greiner P.L., Myers S., Peng R., Federspiel K.W., Russell M.J., LaRusso S.J., Nicholas F. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 2006, 44:1465-1477.
8. McDonald C., Erlichman C., Ingle J., Rosales G., Allen C., Greiner S., Harvey M., Zollman P., Russell S., Galanis E. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res. Treat. 2006, 99:177-184.
9. Iankov I.D., Msaouel P., Allen C., Federspiel M.J., Bulur P.A., Dietz A.B., Gastineau D., Ikeda Y., Ingle J.N., Russell S.J., Galanis E. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res. Treat. 2010, 122:745-754.
10. Dingli D., Peng K.W., Harvey M.E., Greipp P.R., O'Connor M.K., Cattaneo R., Morris J.C., Russell S.J. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004, 103:1641-1646.
11. Grote D., Russell S.J., Cornu T.I., Cattaneo R., Vile R., Poland G.A., Fielding A.K. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001, 97:3746-3754.
12. Tong A.P., Wu L.H., Lin Q.S., Lau Q.C., Zhao X., Li J., Chen P., Chen L.J., Tang H., Huang C.H., Wei Y.Q. Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics 2008, 8:2012-2023.
13. Tong A.P., Gou L.T., Lau Q.C., Chen B., Zhao X., Li J., Tang H., Chen L.J., Tang M.H., Huang C.H., Wei Y.Q. Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis B virus x protein. J. Proteom. Res. 2009, 8:1037-1046.
14. Go E.P., Wikoff W.R., Shen Z.X., O'Maille G., Morita H., Conrads T.P., Nordstrom A., Trauger S.A., Uritboonthai W., Lucas D.A., Chan K.C., Veenstra T.D., Lewicki H., Oldstone M.B., Schneemann A., Siuzdak G. Mass spectrometry reveals specific and global molecular transformations during viral infection. J. Proteom. Res. 2006, 5:2405-2416.
15. van Diepen A., Brand H.K., Sama I., Lambooy H.J., van den Heuvel L.P., van der Well L., Huynen M., Osterhaus A., Andeweg A.C., Hermans P.W.M. Quantitative proteome profiling of respiratory virus-infected lung epithelial cells. J. Proteom. 2010, 73:1680-1693.
16. Hasegawa K.T., Nakamura M., Harvey Y., Ikeda A., Oberg M., Figini M., Canevari S., Hartmann L.C., Peng K.W. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin. Cancer Res. 2006, 12:6170-6178.
17. Blechacz B., Splinter P.L., Greiner S., Myers R., Peng K.W., Federspiel M.J., Russell S.J., LaRusso N.F. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 2006, 44:1465-1477.
18. Bremer E., van Dam G., Kroesen B.J., de Leij L., Helfrich W. Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol. Med. 2006, 12:382-393.
19. Balachandran S., Porosnicu M., Barber G.N. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J. Virol. 2001, 75:3474-3479.
20. Kwon O.J., Kim P.H., Huyn S., Wu L., Kim M., Yun C.O. A hypoxia- and α-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin. Cancer Res. 2010, 16:6071-6082.
21. Friedman G.K., Pressey J.G., Reddy A.T., Markert J.M., Gillespie G.Y. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol. Ther. 2009, 17:1125-1135.
22. Thirukkumaran C.M., Nodwell M.J., Hirasawa K., Shi Z.Q., Diaz R., Luider J., Johnston R.N., Forsyth P.A., Magliocco A.M., Lee P., Nishikawa S., Donnelly B., Coffey M., Trpkov K., Fonseca K., Spurrell J., Morris D.G. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res. 2010, 70:2435-2444.
23. Angelova A.L., Aprahamian M., Balboni G., Delecluse H.J., Feederle R., Kiprianova I., Grekova S.P., Galabov A.S., Witzens-Harig M., Ho A.D., Rommelaere J., Raykov Z. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: in vitro and in vivo studies. Mol. Ther. 2009, 17:1164-1172.
24. Schirrmacher V., Fournier P. Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol. Biol. 2009, 542:565-605.
25. Chu W., Li X., Li C., Wan L., Shi H., Song X., Liu X., Chen X., Zhang C., Shan H., Lu Y., Yang B. TGFBR3, a potential negative regulator of TGF-β signaling, protects cardiac fibroblasts from hypoxia-induced apoptosis. J. Cell. Physiol. 2011, 226:2586-2594.
26. Raza H., John A., Benedict S. Acetylsalicylic acid-induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial dysfunction in human hepatoma HepG2 cells. Eur. J. Pharmacol. 2011, 668:15-24.
27. Wu H.M., Schally A.V., Cheng J.C., Zarandi M., Varga J., Leung P.C. Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21. Cancer Lett. 2010, 298:16-25.
28. Ye L., Zhang B., Seviour E.G., Tao K.X., Liu X.H., Ling Y., Chen J.Y., Wang G.B. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett. 2011, 307:6-17.
29. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 2009, 8:579-591.
30. Waris G., Huh K.W., Siddiqui A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress. Mol. Cell. Biol. 2001, 21:7721-7730.
31. Gloire G., Legrand-Poels S., Piette J. NF-kappa B activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 2006, 72:1493-1505.
32. Rush J.W.E., Turk J.R., Laughlin M.H. Exercise training regulates SOD-1 and oxidative stress in porcine aortic endothelium. Am. J. Physiol. - Heart Circul. Physiol. 2003, 284:1378-1387.
33. Li J.Y., Liu R., Lei Y.L., Wang K., Lau Q.C., Xie N., Zhou S.T., Nie C.L., Chen L.J., Wei Y.Q., Huang C.H. Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy 2010, 6:711-724.
34. Drakulic T., Temple M.D., Guido R., Jarolim S., Breitenbach M., Attfield P.V., Dawes I.W. Involvement of oxidative stress response genes in redox homeostasis, the level of reactive oxygen species, and ageing in Saccharomyces cerevisiae. Fems Yeast Res. 2005, 5:1215-1228.
35. Hayashida Y.K., Honda M., Idogawa Y., Ino M., Ono A., Tsuchida A., Aoki T., Hirohashi S., Yamada T. E-cadherin regulates the association between beta-catenin and actinin-4. Cancer Res. 2005, 65:8836-8845.
36. Peluso J.J., Pappalardo A., Fernandez G. E-cadherin-mediated cell contact prevents apoptosis of spontaneously immortalized granulosa cells by regulating Akt kinase activity. Biol. Reprod. 2001, 64:1183-1190.
37. Al Moustafa A.E., Yen L., Benlimame N., Alaoui-Jamali M.A. Regulation of E-cadherin/catenin complex patterns by epidermal growth factor receptor modulation in human lung cancer cells. Lung Cancer 2002, 37:49-56.
38. Wijnhoven B.P.L., Dinjens W.N.M., Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Brit. J. Surg. 2000, 87:992-1005.
39. Luther M.J., Davies E., Muller D., Harrison M., Bone A.J., Persaud S.J., Jones P.M. Cell-to-cell contact influences proliferative marker expression and apoptosis in MIN6 cells grown in islet-like structures. Am. J. Physiol. - Endocrinol. Metabol. 2005, 288:E502-E509.
40. Park M.Y., Lee R.H., Lee S.H., Jung J.S. Apoptosis induced by inhibition of contact with extracellular matrix in mouse collecting duct cells. Nephron 1999, 83:341-351.
41. Takeuchi T., Suzuki M., Kumagai J., Kamijo T., Sakai M., Kitamura T. Extracellular matrix dermatopontin modulates prostate cell growth in vivo. J. Endocrinol. 2006, 190:351-361.
42. Kouniavsky G., Khaikin M., Zvibel I., Zippel D., Brill S., Halpern Z., Papa M. Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. Clin. Exp. Metast. 2002, 19:55-60.
43. Lim S.O., Gu J.M., Kim M.S., Kim H.S., Park Y.N., Park C.K., Cho J.W., Park Y.M., Jung G. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 2008, 135:2128-2140.
44. Zemach A., McDaniel I.E., Silva P., Zilberman D. Genome-wide evolutionary analysis of eukaryotic DNA methylation. Science 2010, 328:916-919.
45. Suzuki M.M., Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 2008, 9:465-476.
46. Zhang Y., Gao Y., Zhang G., Huang S., Dong Z., Kong C., Su D., Du J., Zhu S., Liang Q., Zhang J., Lu J., Huang B. DNMT3a plays a role in switches between doxorubicin-induced senescence and apoptosis of colorectal cancer cells. Int. J. Cancer 2011, 128:551-561.